CDEK
← All drugs Report issue

saroglitazar

Small moleculeexperimental

Saroglitazar is a drug for the treatment of type 2 diabetes mellitus, dyslipidemia, NASH and NAFLD It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients. — Wikipedia

Clinical trial activity

23 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
13
Phase 3
5
Phase 4
1

Earliest trial started Jun 1, 2009 (NCT00924430)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2014

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(=O)O
Mol. weight
439.58 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • alpha-ethoxy-4-(2-(2-methyl-5-(4-methylthio)phenyl))-1h-pyrrol-1-yl)ethoxy))benzenepropanoic acid
  • alpha-ethoxy-4-(2-(2-methyl-5-(4-methylthio)phenyl))-1h-pyrrol-1-yl)ethoxy))benzenepropanoic acid magnesium salt
  • lipaglyn
  • saroglitazar
  • saroglitazar
  • saroglitazar
  • saroglitazar
  • saroglitazar
  • saroglitazar
  • saroglitazar magnesium
  • saroglitazar magnesium
  • saroglitazar magnesium
  • slv337
  • zyh1
  • zyh1 compound

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07216235Phase 3Dec 31, 2025Zydus Discovery DMCC
NCT06825559Phase 1Mar 31, 2025Zydus Discovery DMCC
NCT06427395Phase 3Jul 16, 2024Zydus Discovery DMCC
NCT05872269Phase 4Jul 20, 2023Zydus Discovery DMCC
NCT05211284Phase 2Jul 1, 2022Zydus Discovery DMCC
NCT05133336Phase 2/Phase 3 (Phase 3)Feb 1, 2022Zydus Discovery DMCC
NCT05045482Phase 1Oct 21, 2021Zydus Discovery DMCC
NCT05011305Phase 2Aug 18, 2021Zydus Discovery DMCC
NCT04446507Phase 1Jul 27, 2020American Research Corporation (ARC), Zydus Discovery DMCC
NCT04469920Phase 1Jul 16, 2020Zydus Discovery DMCC
NCT04193982Phase 3Jan 1, 2020Asian Institute of Gastroenterology
NCT04112446Phase 1Sep 20, 2019Covance, Zydus Discovery DMCC
NCT04045769Phase 1Aug 31, 2019Zydus Discovery DMCC
NCT03863574Phase 2Jun 1, 2019Zydus Discovery DMCC
NCT03617263Phase 2Sep 30, 2018Cadila Healthcare, Zydus Discovery DMCC
NCT03639623Phase 2Aug 23, 2018Zydus Discovery DMCC
NCT03061721Phase 2Apr 6, 2017Zydus Discovery DMCC
NCT03097107Phase 2Apr 6, 2017Zydus Discovery DMCC
NCT03112681Phase 2Apr 1, 2017Zydus Discovery DMCC
NCT02265276Phase 3Oct 1, 2014Command Hospital, India
Showing 20 of 23 trials
Page 1 / 2

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Zydus Discovery DMCCFor profit181842017
AbbottFor profit2222009
American Research Corporation (ARC)For profit1012020
Asian Institute of GastroenterologyAcademic/Hospital1112020
Cadila HealthcareFor profit1012018
Command Hospital, IndiaAcademic/Hospital1112014
CovanceFor profit1012019
IQVIAFor profit1012009
SolvayFor profit1112009
9 organizations
Page 1 / 1